Vor Biopharma (NYSE:VOR) Upgraded to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Vor Biopharma (NYSE:VOR) from a sell rating to a hold rating in a report published on Wednesday morning, Zacks.com reports.

According to Zacks, “Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. is based in CAMBRIDGE, Mass. “

Shares of VOR stock opened at $14.66 on Wednesday. The business’s 50 day moving average is $14.52 and its two-hundred day moving average is $19.96. The company has a market cap of $544.55 million and a PE ratio of -0.06. Vor Biopharma has a 12 month low of $11.78 and a 12 month high of $63.62.

Vor Biopharma (NYSE:VOR) last announced its quarterly earnings data on Sunday, August 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). On average, sell-side analysts expect that Vor Biopharma will post -2.38 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Citigroup Inc. acquired a new stake in shares of Vor Biopharma in the first quarter worth $33,000. Royal Bank of Canada bought a new position in Vor Biopharma in the first quarter worth $46,000. Bourgeon Capital Management LLC bought a new position in Vor Biopharma in the second quarter worth $34,000. Rhumbline Advisers lifted its position in Vor Biopharma by 20.1% in the second quarter. Rhumbline Advisers now owns 11,537 shares of the company’s stock worth $215,000 after purchasing an additional 1,929 shares during the period. Finally, New York State Common Retirement Fund lifted its position in Vor Biopharma by 31.3% in the second quarter. New York State Common Retirement Fund now owns 11,292 shares of the company’s stock worth $211,000 after purchasing an additional 2,692 shares during the period. Institutional investors and hedge funds own 82.85% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc, early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells.

See Also: Outperform Rating

Get a free copy of the Zacks research report on Vor Biopharma (VOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Vor Biopharma (NYSE:VOR)

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.